脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究

doi:10.11904/j.issn.1002-3070.2023.02.011

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (2): 155-159.doi: 10.11904/j.issn.1002-3070.2023.02.011

脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究

冯诚天, 黄芙蓉综述, 姜永冬审校

哈尔滨医科大学附属肿瘤医院乳腺外科一病区(哈尔滨 150081)

收稿日期:2022-11-14 修回日期:2023-03-17 发布日期:2023-05-30
通讯作者: 姜永冬,E-mail:jiangyongdonghmu@126.com
作者简介:冯诚天,男,(1996-),硕士研究生,从事乳腺分子流行病学的研究。
基金资助:
黑龙江省博士后科研基金(编号:LBH-Q20133)

Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer

FENG Chengtian, HUANG Furong, JIANG Yongdong

The First Ward of Mammary Gland,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2022-11-14 Revised:2023-03-17 Published:2023-05-30

摘要/Abstract

摘要： 曲妥珠单抗的出现极大地改善了HER2阳性乳腺癌患者的预后,但仍有一部分患者在治疗过程中出现原发性或继发性的曲妥珠单抗耐药。近年来,曲妥珠单抗的耐药机制越来越受到关注,但耐药现象尚未完全阐明。脂质代谢作为维持细胞生存的基本生理活动,与HER2阳性乳腺癌细胞产生靶向治疗耐药性有着密切的关系,有望成为治疗曲妥珠单抗耐药的新靶点。本文就脂质代谢与曲妥珠单抗耐药性机制之间的相关性作一综述。

关键词: 脂质代谢, HER2阳性乳腺癌, 耐药性

Abstract: The emergence of trastuzumab has greatly improved the prognosis of patients with HER2-positive breast cancer,but some patients still develop primary or secondary trastuzumab resistance during treatment.In recent years,the drug resistance mechanism of trastuzumab has attracted more and more attention,but the drug resistance phenomenon has not been fully elucidated.Lipid metabolism,as a basic physiological activity to maintain cell survival,is closely related to the resistance of HER2-positive breast cancer cells to targeted therapy,and is expected to become a new target for the treatment of trastuzumab resistance.This article reviews the relationship between lipid metabolism and the mechanism of trastuzumab resistance.

Key words: Lipid metabolism, HER2 positive breast cancer, Drug resistance

中图分类号:

R737.9

冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.

FENG Chengtian, HUANG Furong, JIANG Yongdong. Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer[J]. Journal of Practical Oncology, 2023, 37(2): 155-159.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.02.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I2/155

参考文献

1 Yan H,Xiao H,Zhu J,et al.Association between the HER2 protein expression level and the efficacy of neoadjuvant chemotherapy in HER2-positive breast cancer[J].Cancer Manag Res,2020,12:12715-12722.
2 Fernandez-nogueira P,Mancino M,Fuster G,et al.Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation[J].Clin Cancer Res,2020,26(6):1432-1448.
3 王星涵,吕雅蕾.曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J].实用肿瘤学杂志,2022,36(5):445-451.
4 Huang C,Freter C.Lipid metabolism,apoptosis and cancer therapy[J].Int J Mol Sci,2015,16(1):924-949.
5 Bian X,Liu R,Meng Y,et al.Lipid metabolism and cancer[J].J Exp Med,2021,218(1):e20201606.
6 Cao Y.Adipocyte and lipid metabolism in cancer drug resistance[J].J Clin Invest,2019,129(8):3006-3017.
7 Feng WW,Wilkins O,Bang S,et al.CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies[J].Cell Rep,2019,29(11):3405-3420.
8 Ligorio F,Pellegrini I,Castagnoli L,et al.Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer[J].Cancer Lett,2021,511:77-87.
9 Han J,Qu H,Han M,et al.MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer[J].Oncogene,2021,40(4):833-847.
10 Jung YY,Kim HM,Koo JS.Expression of lipid metabolism-related proteins in metastatic breast cancer[J].PLoS One,2015,10(9):e0137204.
11 Vazquez-martin A,Colomer R,Brunet J,et al.Pharmacological blockade of fatty acid synthase(FASN)reverses acquired autoresistance to trastuzumab(Herceptin^im)by transcriptionally inhibiting′HER2 super-expression′occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells[J].Int J Oncol,2007,31(4):769-776.
12 Ravacci GR,Brentani MM,Tortelli TC,et al.Docosahexaenoic acid modulates a HER2-associated lipogenic phenotype,induces apoptosis,and increases Trastuzumab action in HER2-overexpressing breast carcinoma cells[J].Biomed Res Int,2015,2015:838652.
13 Menendez JA.Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth:molecular mechanisms and therapeutic perspectives[J].Biochim Biophys Acta,2010,1801(3):381-391.
14 Mao Y,Zhang Y,Qu Q,et al.Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells[J].Mol Biosyst,2015,11(4):1029-1040.
15 Griner SE,Wang KJ,Joshi JP,et al.Mechanisms of adipocytokine-mediated Trastuzumab resistance in HER2-positive breast cancer cell lines[J].Curr Pharmacogenomics Person Med,2013,11(1):31-41.
16 Duong MN,Cleret A,MAtera EL,et al.Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity[J].Breast Cancer Res,2015,17(1):57.
17 ROdriguez-barrueco R,Yu J,SAucedo-cuevas LP,et al.Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers[J].Genes Dev,2015,29(15):1631-1648.
18 Liu S,Lee J S,Jie C,et al.HER2 overexpression triggers an IL1alpha proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance[J].Cancer Res,2018,78(8):2040-2051.
19 Manore SG,Doheny DL,Wong GL,et al.IL-6/JAK/STAT3 signaling in breast cancer metastasis:biology and treatment[J].Front Oncol,2022,12:866014.
20 Korkaya H,Kim GI,Davis A,et al.Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population[J].Mol Cell,2012,47(4):570-584.
21 Felcher CM,Bogni ES,Kordon EC.IL-6 cytokine family:A putative target for breast cancer prevention and treatment[J].Int J Mol Sci,2022,23(3).
22 Mercogliano MF,Bruni S,ElizaLDE PV,et al.Tumor necrosis factor alpha blockade:an opportunity to tackle breast cancer[J].Front Oncol,2020,10:584.
23 Hermawan A,Putri H.Integrative bioinformatics analysis reveals potential target genes and TNFα signaling inhibition by brazilin in metastatic breast cancer cells[J].Asian Pac J Cancer Prev,2020,21(9):2751-2762.
24 Song PN,Mansur A,Dugger KJ,et al.CD4 T-cell immune stimulation of HER2+ breast cancer cells alters response to trastuzumab in vitro[J].Cancer Cell Int,2020,20(1):544.
25 Mercogliano MF,DE martino M,VenTurutti L,et al.TNFα-induced mucin 4 expression elicits Trastuzumab resistance in HER2-positive breast cancer[J].Clin Cancer Res,2017,23(3):636-648.
26 Rio M C,Dali-youcef N,Tomasetto C.Local adipocyte cancer cell paracrine loop:can“sick fat”be more detrimental?[J].Horm Mol Biol Clin Investig,2015,21(1):43-56.
27 Bielczyk-maczynska E.White adipocyte plasticity in physiology and disease[J].Cells,2019,8(12):1507.
28 Okumura T,Ohuchida K,Kibe S,et al.Adipose tissue-derived stromal cells are sources of cancer-associated fibroblasts and enhance tumor progression by dense collagen matrix[J].Int J Cancer,2019,144(6):1401-1413.
29 陈都,钱诚.乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J].实用肿瘤学杂志,2020,34(4):382-386.
30 Luque M,Sanz-alvarez M,Santamaria A,et al.Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer[J].Int J Mol Sci,2021,22(24):13297.
31 Zhong H,Davis A,Ouzounova M,et al.A Novel IL6 antibody sensitizes multiple tumor types to chemotherapy including Trastuzumab-resistant tumors[J].Cancer Res,2016,76(2):480-490.

[1]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.
[2]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.
[3]	池淑琦综述, 汪宏波审校. 长链非编码RNA与肿瘤耐药性的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 150-153.
[4]	潘夏综述, 江建平审校. Alectinib在非小细胞肺癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 75-79.
[5]	陈可心,李,琛,秦,誉,姚国栋,综述,耿敬姝,审校. 星形细胞上调基因1(AEG-1)介导肿瘤耐药的研究进展[J]. 实用肿瘤学杂志, 2014, 28(5): 447-450.
[6]	张超, 杨春辉综述, 孟秀香审校. Bmi-1基因与肿瘤多药耐药性的关系[J]. 实用肿瘤学杂志, 2013, 27(4): 367-371.
[7]	李占文;杨华锋;胡云锵;李振平;刘纯;范风风. 112例乳腺癌P-gp表达与临床病理相关因素分析[J]. 实用肿瘤学杂志, 2006, 20(05): 419-420.
[8]	野丽莉;张淑芳;史艳双. 肿瘤患者凝固酶阴性葡萄球菌的耐药性观察[J]. 实用肿瘤学杂志, 2001, 15(04): 310-311.

脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究

Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价